{"id":56834,"date":"2026-02-11T00:27:02","date_gmt":"2026-02-10T16:27:02","guid":{"rendered":"https:\/\/flcube.com\/?p=56834"},"modified":"2026-02-11T00:27:03","modified_gmt":"2026-02-10T16:27:03","slug":"changchun-high-techs-gensci136-wins-nmpa-approval-for-iga-nephropathy-clinical-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56834","title":{"rendered":"Changchun High-Tech\u2019s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial"},"content":{"rendered":"\n

Changchun High & New Technology Industries (Group) Inc.<\/strong> (SHE:\u202f000661<\/a><\/strong>) announced that its subsidiary Changchun GeneScience Pharmaceutical Inc.<\/strong> has received clinical trial approval<\/strong> from the National Medical Products Administration (NMPA)<\/strong> for GenSci136<\/strong>, a Category 1 biologic product<\/strong> targeting Immunoglobulin A nephropathy (IgAN)<\/strong>. The trimeric BCMA fusion protein<\/strong> represents a novel mechanism<\/strong> for addressing humoral immune dysregulation<\/strong> in autoimmune diseases, with potential for long-term administration<\/strong> without prophylactic anti-infective therapy.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Parent Company<\/strong><\/td>Changchun High & New Technology Industries (SHE:\u202f000661)<\/td><\/tr>
Subsidiary<\/strong><\/td>Changchun GeneScience Pharmaceutical Inc.<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Asset<\/strong><\/td>GenSci136 \u2013 Trimeric BCMA fusion protein<\/td><\/tr>
Classification<\/strong><\/td>Category 1 innovative biologic<\/td><\/tr>
Approval<\/strong><\/td>Clinical trial authorization for IgA nephropathy (IgAN)<\/td><\/tr>
Therapeutic Focus<\/strong><\/td>Autoimmune diseases with pathogenic antibody mediation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Platform & Mechanism of Action<\/h2>\n\n\n\n
Feature<\/th>GenSci136 Specification<\/th>Strategic Differentiation<\/th><\/tr><\/thead>
Structure<\/strong><\/td>Trimeric BCMA fusion protein<\/strong><\/td>Mimics natural extracellular domain; enhanced ligand blocking vs. monomeric formats<\/td><\/tr>
Target Ligands<\/strong><\/td>BAFF and APRIL<\/strong> (homotrimers and heterotrimers)<\/td>Dual blockade of B-cell survival signals; upstream intervention vs. B-cell depletion<\/td><\/tr>
Mechanism<\/strong><\/td>Inhibits B lymphocyte and plasma cell survival\/differentiation<\/td>Addresses root cause<\/strong> of autoantibody production vs. symptomatic management<\/td><\/tr>
Pharmacokinetics<\/strong><\/td>Extended in vivo half-life<\/strong><\/td>Reduced dosing frequency; improved patient compliance<\/td><\/tr>
Safety Profile<\/strong><\/td>No prophylactic anti-infective treatment required<\/strong><\/td>Differentiation from B-cell depleting therapies (rituximab, belimumab)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Indication: IgA Nephropathy<\/h2>\n\n\n\n
Parameter<\/th>IgAN Profile<\/th>GenSci136 Value Proposition<\/th><\/tr><\/thead>
Disease Burden<\/strong><\/td>Most common primary glomerulonephritis globally<\/strong>; 30-40% progress to end-stage renal disease<\/td>Disease-modifying therapy to prevent dialysis\/transplantation<\/td><\/tr>
Pathophysiology<\/strong><\/td>Galactose-deficient IgA1 (Gd-IgA1) immune complexes deposit in mesangium; driven by mucosal B-cell\/plasma cell overactivity<\/td>BCMA-BAFF\/APRIL blockade reduces pathogenic IgA-producing cells<\/td><\/tr>
Current Standard<\/strong><\/td>RAAS inhibitors, SGLT2 inhibitors, budesonide (Nefecon)<\/td>Limited efficacy; no approved biologics specifically targeting IgAN immunopathogenesis<\/td><\/tr>
Unmet Need<\/strong><\/td>No approved therapy targeting humoral immune dysregulation<\/strong><\/td>First-in-class potential for BCMA fusion protein in nephrology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Positioning & Pipeline Expansion<\/h2>\n\n\n\n
Factor<\/th>Strategic Value<\/th><\/tr><\/thead>
Category 1 Status<\/strong><\/td>NMPA innovative biologic designation<\/strong> provides regulatory fast-track, market exclusivity, and NRDL listing priority<\/td><\/tr>
Platform Potential<\/strong><\/td>BCMA-BAFF\/APRIL mechanism applicable to multiple autoimmune diseases<\/strong>: lupus nephritis, rheumatoid arthritis, myasthenia gravis<\/td><\/tr>
Long-Term Administration<\/strong><\/td>No anti-infective prophylaxis<\/strong> requirement enables chronic disease management<\/strong> vs. safety-limited B-cell depleters<\/td><\/tr>
GeneScience Heritage<\/strong><\/td>Subsidiary of Changchun High-Tech<\/strong> (major Chinese biopharma); leverages established biologics manufacturing and regulatory expertise<\/td><\/tr>
Global Differentiation<\/strong><\/td>While telitacicept<\/strong> (RemeGen, BAFF\/APRIL inhibitor) approved in China for IgAN, GenSci136’s trimeric BCMA format<\/strong> offers distinct mechanism<\/strong> and potential combination\/superiority positioning<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development Roadmap<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>Phase I\/II clinical trial initiation (NMPA approved)<\/td>Q1 2026<\/td><\/tr>
Near-term<\/strong><\/td>Dose-ranging and proof-of-concept in IgAN patients<\/td>2026-2027<\/td><\/tr>
Expansion<\/strong><\/td>Additional autoimmune indications (lupus nephritis, RA)<\/td>2027-2028<\/td><\/tr>
Regulatory<\/strong><\/td>NDA submission for IgAN based on Phase II\/III data<\/td>2028-2029<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding GenSci136 clinical development in IgA nephropathy, BCMA fusion protein mechanism validation, and Changchun GeneScience’s autoimmune pipeline expansion. Actual results may differ due to Phase I\/II safety outcomes, competitive dynamics with BAFF\/APRIL inhibitors (telitacicept, atacicept), and IgAN trial enrollment challenges.-Fineline Info & Tech<\/a><\/p>\n\n\n\n